TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01703481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42756493: Part 1
Description: Participants will receive 0.5 mg (starting dose) capsule of JNJ-42756493 orally (by mouth) once daily on Day 1 of Cycle 1. Dose of the study medication will be escalated sequentially till the dose limiting toxicity is achieved to determine the recommended part 2 doses (RP2D).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42756493: Part 2
Description: Participants will receive JNJ-42756493 at the RP2D or below RP2D (maximum tolerated dose from Part 1) orally once daily on a 21 days cycle to confirm RP2D (in Part 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42756493: Part 3
Description: Participants will receive JNJ-42756493 at first RP2D of 9 mg daily in Part 3 orally once daily on a 21 days cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42756493: Part 3
Description: Participants will receive JNJ-42756493 at first RP2D of 9 mg daily in Part 3 orally once daily on a 21 days cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42756493: Part 3
Description: Participants will receive JNJ-42756493 at first RP2D of 9 mg daily in Part 3 orally once daily on a 21 days cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42756493: Part 3
Description: Participants will receive JNJ-42756493 at first RP2D of 9 mg daily in Part 3 orally once daily on a 21 days cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42756493: Part 4
Description: Participants will receive JNJ-42756493 second RP2D of 10 mg intermittent dosing in Part 4 (with option to increase to 12 mg intermittent dosing based on phosphate level), orally on an intermittent schedule of daily for 7 days followed by 7 days off with a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42756493: Part 4
Description: Participants will receive JNJ-42756493 second RP2D of 10 mg intermittent dosing in Part 4 (with option to increase to 12 mg intermittent dosing based on phosphate level), orally on an intermittent schedule of daily for 7 days followed by 7 days off with a 28-day cycle.
Study: NCT01361789

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: parecoxib, valdecoxib, parecoxib and dexamethasone
Description: combination of both drugs
Study: NCT00525200

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluoruracil, Cisplatinum
Description: 5 FU 1000mg/m2; days 1-5; 3 cycles: q21~Cisplatin 80mg/m2; day 1; 3 cycles: q21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75mg/m2, day 1; 3 cycles; q21
Study: NCT01958047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3652
Description: Oral
Study: NCT04004806

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hill Rom tracking device
Description: Location tracking devices from Hill Rom company.
Study: NCT01670942

Intervention type: OTHER
Intervention: hypobaric chamber
Description: We will use a large (26 tons) multi-place hyperbaric and hypobaric chamber at IMC in Murray, Utah (elevation 1500m or 4500ft, average ambient barometric pressure 645mm Hg). In the hypobaric study, the barometric pressure will be lowered to 554mm Hg (phase 1) or 471mm Hg (phase 2) over 20 minutes and held there for two hours.
Study: NCT00234299

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 325mg, one tablet orally, six months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 325mg, one tablet orally every day, 6 months
Study: NCT02420847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib Citrate
Description: Given PO
Study: NCT03196622

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Handgrip test
Description: Handgrip strenght can be used in daily clinical practice to screen patients having sarcopenia to improve treatment and quality of life.
Study: NCT03460132

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tomas® Anchorage System - DENTAURUM
Description: self drilling, bone inserted, screw like device used for anchorage preparation during orthodontic treatment.
Study: NCT00825513

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Akreos Toric IOL
Description: Lens implant following cataract surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Akreos Advanced Optics Aspheric Intraocular Lens (Akreos AO)
Description: Lens implant following cataract surgery
Study: NCT02879669

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ONCOS-102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed/cisplatin (carboplatin)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed/cisplatin (carboplatin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study: NCT01964118

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting group
Description: Intermittent fasting for 12 months

Intervention type: OTHER
Group type: OTHER
Intervention: control group
Description: usual diet for 6 months and intermittent fasting for other 6 months
Study: NCT03394508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALK Alutard birch or 5-grasses
Description: Intralymphatic injection with 1000 units. 3 injections with 4-5 weeks interval (0,1 ml) and one additional booster injection with 1000 units before the second pollen season.
Study: NCT03067779

Intervention type: OTHER
Group type: OTHER
Intervention: mHealth Tool
Description: The curriculum in the mHealth tool was derived in consultation with patient safety, informatics and adult educational curricula experts, and is comprised of clinical vignettes describing common patient safety themes in CKD and includes a pre- and post-test knowledge assessment. Topics of emphasis included NSAID risk awareness, hypoglycemia awareness, avoidance of volume depletion when ill (Sick Day Protocol) and avoidance of contrast-induced nephropathy.
Study: NCT01434823

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nocturnal coverage
Description: The investigators will randomize, by week, nocturnal coverage. During the intervention weeks, intensivists will be in the MICU from 7pm until 7am.~For the Intensivist Sleep and Work sub-study:~Measurements of Daytime Intensivist work hours, sleep, and attention will be measured with actigraphy, PVT, Sleep and Work Diaries, and Surveys. Results will be compared between periods with standard staffing to periods with overnight intensivist coverage.
Study: NCT00622427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: 8 mg tablets every night for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo tablets for every night for 2 weeks
Study: NCT01229475

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation with stepwise approach
Description: Stepwise approach for repeat AF ablation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation with stepwise approach
Description: Stepwise approach for repeat AF ablation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Linear ablation
Description: Linear ablation for AF ablation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Linear ablation
Description: Linear ablation for AF ablation
Study: NCT02967952

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: supraglottic airway (SGA) V.S. endotracheal intubation (ETI)
Description: already being described above

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: supraglottic airway (SGA) V.S. endotracheal intubation (ETI)
Description: already being described above
Study: NCT04214691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen tablet will be administered orally in treatment sequence 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen tablet will be administered orally in treatment sequence 1 and 2.
Study: NCT01045291

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Resynchronization Therapy-Defibrillator (CRT-D)
Description: Market approved InSync Sentry™ model 7298, dual chamber Implantable Cardioverter Defibrillator (ICD) with Cardiac Resynchronization Therapy (CRT) including sequential biventricular pacing and OptiVol® fluid monitoring or market approved InSync Maximo™ model 7304 dual chamber ICD with CRT including sequential biventricular pacing.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy-Defibrillator (CRT-D)
Description: Market approved InSync Sentry™ model 7298, dual chamber Implantable Cardioverter Defibrillator (ICD) with Cardiac Resynchronization Therapy (CRT) including sequential biventricular pacing and OptiVol® fluid monitoring or market approved InSync Maximo™ model 7304 dual chamber ICD with CRT including sequential biventricular pacing.
Study: NCT04135716

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Colonoscopy with assistance of Endo.Angel
Description: Patients in exposed group will receive colonoscopy with assistance of Endo.Angel,a real-time quality monitoring system based on computer vision,which is used to monitor the velocity of insertion of the endoscope, record the time of insertion and withdrawal of the endoscope, and remind endoscopists of the blind areas caused by intestinal segment slipping.

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Colonoscopy without assistance of Endo.Angel
Description: Patients in non-exposed group will receive colonoscopy without assistance of Endo.Angel.
Study: NCT01873482

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Movement to rhythm
Description: Movement to rhythm
Study: NCT02703103

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual chest compressions
Description: 2 min of Chest compressions without mechanical chest compression system

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual chest compressions
Description: 2 min of Chest compressions without mechanical chest compression system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARM chest compressions
Description: 2 min of Chest compressions with mechanical chest compression system LifeLine ARM

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARM chest compressions
Description: 2 min of Chest compressions with mechanical chest compression system LifeLine ARM
Study: NCT01024400

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Non-adjuvanted A(H1N1)v influenza vaccine
Description: 15 mcg HA/0.5 ml
Study: NCT01376011

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: quercetin/placebo
Description: Quercetin 500mg once per day versus placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: quercetin/placebo
Description: Quercetin 500mg once per day versus placebo
Study: NCT03438435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QRH-882260 Heptapeptide
Description: Imaging agent
Study: NCT02550964

Intervention type: PROCEDURE
Intervention: Composite Examination
Description: First, patients will get the baseline ophthalmologic exam and medical evaluation by physicians. As a diagnostic method, the composite examination including fundus photography, fundus autofluorescence, spectral-domain optical coherence tomography, Humphrey visual field test and multifocal electroretinography will be tested once every year.
Study: NCT02484105

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comforting Conversation
Description: Pain management, distraction, diversion, empathy. Dependent on qualitative study results.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Communication
Description: Information on procedure type, duration, findings, key landmarks, possibility of analgesic treatment, pause in procedure.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Communication
Description: Information on procedure type, duration, findings, key landmarks, possibility of analgesic treatment, pause in procedure.
Study: NCT01980849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadroparin, long term

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nadroparin: short-term
Study: NCT03215355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primovist
Description: Primovist is currently a drug marketed for MRI. In this study it will be administered intravenously at 4 times what it is quoted for MRI to enhance the different imaging modality (CBCT) to improve the accuracy of liver SBRT. Although liver SBRT usually consists of 5 treatments, contrast will only be administered during the first treatment.~Consulting Health Canada and Bayer HealthCare Canada (the drug manufacturer) deemed this use off label dosing which in Canada is at the discretion of the physician. Based on preliminary imaging testing, and a review of toxicity literature for this drug, the administration for this specific use was deemed appropriate to give adequate image quality, while simultaneously maintaining patient safety.
Study: NCT04543552

Intervention type: DEVICE
Intervention: Bladder scan
Description: Bladder Scanner, or Biocon-900 is an ultrasonic imaging device that has been developed to measure post-void residual volume of the bladder non-invasively. The images and measurements are obtained by applying a probe onto the abdomen (i.e. bladder). As it scans, the scanner constructs 12 cross-sectional images at 15 degree interval using the reflection signals from urine in the bladder and extracts the position of the bladder wall as well. During urodynamic studies, the bladder scan will measure the infused volume in order to assess difference between the infused and scanned volumes.
Study: NCT03126981

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1.5 oz of whole, natural almonds
Description: 1.5 oz of whole, natural almonds

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low-fat, high refined starches/sugars
Description: Low-fat foods, high in refined starches and added sugars
Study: NCT00807781

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mammaglobin-A DNA vaccine
Study: NCT02206113

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standing workstation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standing workstation
Study: NCT03228680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follitropin delta
Description: Single daily subcutaneous administration through pre-filled injection pen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin beta
Description: Single daily subcutaneous injection in the abdomen
Study: NCT03318848

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video during simulation
Description: The intervention group simulated the bed bath while watching the video, under the supervision of the tutor
Study: NCT02476396

Intervention type: PROCEDURE
Intervention: Carotid Endarterectomy or Stenting
Description: Carotid endarterectomy is a procedure to treat carotid artery disease. This disease occurs when fatty, waxy deposits build up in one of the carotid arteries. The carotid arteries are blood vessels located on each side of your neck (carotid arteries).~This buildup of plaques (atherosclerosis) may restrict blood flow to your brain. Removing plaques causing the narrowing in the artery can improve blood flow in your carotid artery and reduce your risk of stroke.~In carotid endarterectomy, you an anesthetic. Your surgeon makes an incision along the front of your neck, opens your carotid artery and removes the plaques that are clogging your artery. Your surgeon then repairs the artery with stitches or a patch made with a vein or artificial material (patch graft).~Source: Mayo Clinic~Carotid stenting uses a expandable metal coil to prevent the artery from narrowing.
Study: NCT03058068

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allo-hMSCs
Description: 1 peripheral intravenous infusion of allogeneic human mesenchymal stem cells (hMSCs)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allo-hMSCs
Description: 1 peripheral intravenous infusion of allogeneic human mesenchymal stem cells (hMSCs)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allo-hMSCs
Description: 1 peripheral intravenous infusion of allogeneic human mesenchymal stem cells (hMSCs)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allo-hMSCs
Description: 1 peripheral intravenous infusion of allogeneic human mesenchymal stem cells (hMSCs)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 peripheral intravenous infusion
Study: NCT03777189

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy
Description: Cognitive-behavioral therapy will be delivered in line with recommendations (e.g., NICE 2017). Format will be guided self help with added content related to physical activity.
Study: NCT04155996

Intervention type: DEVICE
Intervention: data collection
Description: Patients will receive a full data acquisition set with CGM sensors, an activity tracker and a smartphone application in which they can log daily events.
Study: NCT03261349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ledipasvir and sofosbuvir
Description: To assess whether Harvoni® (ledipasvir and sofosbuvir) could eradicate HCV and lead to durable complete remission of these lymphomas.
Study: NCT02002897

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional carbon dioxide laser
Description: Fractional carbon dioxide laser (10,600 nm), a session once per month, total of 3 sessions with full clinical evaluation and investigations before and one month after the last session of treatment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultraviolet A1 phototherapy (UVA1)
Description: localized UVA1 phototherapy (340-400 nm), low dose irradiation, at a rate of 3 sessions per week , total of 24 sessions with full clinical evaluation and investigations before and after treatment and clinical follow up one month after treatment.
Study: NCT01863446

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lighting1
Description: Ocular light exposure to a red wavelength light

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lighting1
Description: Ocular light exposure to a red wavelength light

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lighting1
Description: Ocular light exposure to a red wavelength light

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lighting2
Description: Ocular light exposure to a blue/green wavelength light

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lighting2
Description: Ocular light exposure to a blue/green wavelength light
Study: NCT01222494

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Weight Loss
Description: This intervention is a family-based, behavioral weight loss program that has been employed in studies with overweight and obese children, as well as with children who have diabetes. For the proposed study, the program has been modified to fit the needs of disruptive and behaviorally disturbed youth and their families. The modified program includes 16 weeks of weekly visits with a study interventionist, and supplemental phone contacts as needed. Phone contacts will only replace in-person visits if absolutely necessary to achieve the visit.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Weight Loss
Description: This intervention is a family-based, behavioral weight loss program that has been employed in studies with overweight and obese children, as well as with children who have diabetes. For the proposed study, the program has been modified to fit the needs of disruptive and behaviorally disturbed youth and their families. The modified program includes 16 weeks of weekly visits with a study interventionist, and supplemental phone contacts as needed. Phone contacts will only replace in-person visits if absolutely necessary to achieve the visit.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Diet and Exercise Education
Description: Participants assigned to this arm will receive monthly medically validated, individualized diet and exercise education by a trained research professional.
Study: NCT01938534

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Helicobacter pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori eradication
Study: NCT03362840

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Start Denver Model
Description: The ESDM is a manualized comprehensive treatment model for young children (12-48 months). In the preschool based ESDM, learning objectives are guided by the ESDM curriculum checklist, which includes developmental skills in language, play, motor skills, personal independence, imitation and cognition. The objectives are monitored for progress during each session The sessions are conducted according to ESDM principles, and include weekly parent-coaching session, in which parents observe the therapist interact with the child while applying various teaching techniques, and then implement these techniques during the interaction with their child. Additionally, parents get acquainted with the daily objective sheet and are encouraged to work on these objectives at home as well. Finally, in this model, therapist adherence to the ESDM practices are monitored according to the ESDM fidelity rating system

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Eclectic preschool intervention
Description: The eclectic approach consists of a combination of methods from several treatment-models. Individualized educational plans are based on multi-disciplinary assessment, and include objectives in several domains - communication, social-skills, play, emotional adjustment, adaptive daily skills, motor skills and cognition. They are presented to parents at the beginning of the year and are reviewed by the staff three times a year.~Parents attend by-weekly counseling-sessions with a professional in order to receive input regarding their child's progress, and discuss issues concerning their child's functioning. All staff members receive supervision at various intensities. However, these usually do not adhere to a single structure and are not guided by official fidelity criteria.
Study: NCT02848118

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A nasal-oral cannula of capnography
Description: After propofol infusion, the complete induction is defined when capnography shows hypoventilation and bronchoscope is then introduced to patients.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observer Assessment of Alertness and Sedation scale
Description: After propofol infusion, the complete induction is defined when OAAS is 3 to 2 (conscious sedation) and bronchoscope is then introduced to patients.